Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum^IV Complexes as Potent Antitumor Agents

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• p53-MDM2 inhibitors face challenges like drug resistance and toxicity in cancer treatment.
• Integrating MDM2 inhibitors with platinum drugs offers a novel therapeutic strategy.

Purpose of the Study:

• To design and synthesize novel platinum(IV)-RG7388 complexes to overcome limitations of current cancer therapies.
• To evaluate the in vitro and in vivo antitumor efficacy and toxicity of these novel complexes.

Main Methods:

• Synthesis of novel Pt(IV)-RG7388 complexes.
• Assessment of antiproliferative activity against wild-type and mutated p53 cancer cells.
• In vivo studies using A549 xenograft models to evaluate tumor growth inhibition and toxicity.
• Cell cycle analysis and apoptosis assays to elucidate mechanisms of action.

Main Results:

• Pt(IV)-RG7388 complexes, particularly 5a and 5b, showed significantly improved antiproliferative activity.
• Complex 5a demonstrated potent in vivo tumor growth inhibition (66.5%) in the A549 xenograft model with no apparent toxicity.
• Complex 5a induced cell cycle arrest at S and G2/M phases and promoted apoptosis through synergistic effects.

Conclusions:

• Pt(IV)-RG7388 complex 5a exhibits excellent in vitro and in vivo antitumor activities.
• These novel complexes hold significant therapeutic potential for cancer treatment, addressing limitations of existing therapies.